Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Redx Pharma has signed an agreement with Canadian-based Pharmascience to license its anti-cancer program that helps the immune system to fight cancer.
Subscribe to our email newsletter
The program is focused on small molecules that prevent a receptor called CSF-1R or cFMS in the body that plays a major role in the immune response to cancer.
As per the license agreement, Redx follows a research, development and commercialization of the Pharmascience program in oncology which is currently at the lead optimization stage.
Redx Pharma chief executive Neil Murray said that helping the immune system to
deal with and target cancer cells is an emerging area of science and the cFMS oncology program and the company has demonstrated the ability to inhibit tumour growth in animal models.
"By in-licensing this program we are able to both enter this important emerging area of cancer research and advance our overall stage of development as a company," Murray added.
Pharmascience Business Development and Strategic Planning director Mathieu Boudreau said that the discovery research team has identified cFMS inhibitor leads and the company is positioned to continue the work that is initiated on this project.
The financial terms of the agreement were not disclosed.